Segment Highlights Company’s Blood Serum Tests For Early Detection of Breast Cancer and Neurodegenerative Diseases
Power3 Medical Products, Inc. (OTCBB: PWRM, https://www.power3medical.com), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, was featured on Fox26 News in Houston.
The segment focused on Power3’s blood serum tests for the early detection of breast cancer and neurodegenerative diseases. News anchor Melissa Wilson toured Power3’s facilities in the Woodlands, Texas and interviewed Steve Rash, CEO of Power3 along with two of the company’s lead investigators, Dr. Essam Sheta and Dr. Ira Goldknopf.
During the interview, Steve Rash discussed the BC-SeraPro™ early detection test for breast cancer. “It is a goal of Power3 Medical to help women because breast cancer is such a terrible disease and there is so much emphasis on the disease,” said Rash. “This test can detect it earlier, which should result in better patient outcomes for breast cancer in most women.”
The piece discussed the need for alternative methods of early detection, citing that some research has found that current methods detect breast cancer after abnormal cells have been in the body for six to ten years. In addition to BC-SeraPro™, the piece highlights the company’s NuroPro® series of blood serum tests for the early detection of neurodegenerative diseases. The story also drew attention to the accuracy of the tests: BC-Sera Pro™ test for the early detection of breast cancer is 90% accurate; NuroPro® test for neurodegenerative diseases is 90% accurate in detecting Alzheimer’s disease and 100% accurate in detecting Parkinson’s disease.
Dr. Goldknopf added, “If you can diagnose Neurodegenerative diseases in their earliest stages, before irreversible damage has been done, you stand a better chance of delaying the progression of the disease.”
“We are delighted to appear on Fox26 news,” said Rash “We believe the development of these tests represents a paradigm shift and a major breakthrough in medicine through the application of proteomics. We are pleased to be featured on such a well-known network.”
The Fox26 News segment can be viewed by visiting: http://www.myfoxhouston.com/myfox/pages/Home/Detail?contentId=5484329 &version=1&locale=EN-US&layoutCode=VSTY&pageId=1.1.1 -- (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro™, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Power3 Medical Products, Inc.
Steven B. Rash, 281-466-1600
srash@power3medical.com
or
The
Investor Relations Group
Investor Relations:
Adam Holdsworth /
Rachel Colgate /
Erica Ruderman, 212-825-3210
or
Media
Relations:
Susan Morgenbesser / Janet Vasquez, 212-825-3210